Carbetocin for Postpartum Hemorrhage: One Injection Instead of an Infusion

The clinical scenario

Postpartum hemorrhage — heavy bleeding after birth — is a leading cause of maternal death worldwide, and preventing it hinges on getting the uterus to contract firmly after delivery. Carbetocin (Duratocin, Pabal) is a long-acting relative of oxytocin designed to make that prevention simpler and more reliable, especially at cesarean birth. This use case explains where it fits; obstetric care is delivered by trained clinicians.

Why the mechanism fits

After the placenta separates, the uterus must clamp down to compress the vessels that fed it. Carbetocin binds the same oxytocin receptors on uterine muscle that oxytocin does, driving a strong, sustained contraction. The difference is duration: oxytocin is broken down within minutes (so it's often given as an infusion), whereas carbetocin's modifications let a single injection sustain uterine tone for about an hour. (See oxytocin in childbirth for the full family of labor peptides.)

The practical advantage

• One dose, not a drip. A single intravenous or intramuscular dose after delivery replaces a continuous oxytocin infusion — convenient at cesarean delivery and where staff or equipment for an infusion are limited.
• Comparable prevention. In clinical use, carbetocin provides effective prevention of postpartum hemorrhage in the settings where it is indicated, with the simplicity of a single administration.

The heat-stable breakthrough

Oxytocin degrades when it isn't kept cold, and maintaining a reliable cold chain is difficult in many low- and middle-income settings — precisely where postpartum hemorrhage causes the most deaths. A heat-stable formulation of carbetocin stays effective without refrigeration. The World Health Organization has recognized heat-stable carbetocin as an option for preventing postpartum hemorrhage where cold storage is unreliable — a genuine advance for global maternal health.

Important boundaries

Carbetocin is used only after the baby is delivered. It is not used to induce or augment labor, because its long, sustained action would be unsafe before birth. Side effects overlap with oxytocin (nausea, flushing, headache, a transient blood-pressure drop), and intravenous doses are given slowly. It is not FDA-approved in the United States, where oxytocin remains standard.

This use case is educational and not medical advice. These medicines are used only within maternity care.